Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.50 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.48 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21034046 | 0.87 | LTB4R2 (0.51) | LTB4R2FTOALDH1A1 | |
| SCHEMBL27539892 | 0.84 | FTO (0.43) | LTB4R2AGTR1FTOALDH1A1DHODH | |
| SCHEMBL12348453 | 0.84 | LTB4R2 (0.58) | LTB4R2AGTR1 | |
| SCHEMBL2963261 | 0.83 | ALDH1A1 (0.61) | ALDH1A1 | |
| SCHEMBL7435938 | 0.81 | LTB4R2 (0.53) | LTB4R2AGTR1 | |
| SCHEMBL10104417 | 0.80 | NOTUM (0.47) | LTB4R2FTOALDH1A1DHODH | |
| SCHEMBL31546405 | 0.80 | NOTUM (0.47) | LTB4R2FTOALDH1A1DHODH | |
| SCHEMBL12475941 | 0.77 | LTB4R2 (0.53) | LTB4R2AGTR1 | |
| SCHEMBL12348454 | 0.76 | AGTR1 (0.55) | AGTR1DHODH | |
| SCHEMBL12348451 | 0.76 | FTO (0.49) | LTB4R2AGTR1FTOALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501750-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-06 | — | — | US | disclosed |
| EP-2253630-A1 | Heterocyclic compound and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
| US-20100137281-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| EP-2151440-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-02-10 | — | — | EP | disclosed |
| US-5438063-A | Hypotensive agents, cardiac insufficiency, increased intraocular pressure, and CNS disorders | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-08-01 | — | — | US | disclosed |
| EP-0657435-A2 | 1,2-Dihydro-2-oxo-pyrimidines | MERCK PATENT GmbH (DE) | 1995-06-14 | — | — | EP | disclosed |
| EP-0628556-A1 | Imidazopyridines | MERCK PATENT GmbH (DE) | 1994-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137281-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | PCSK9, APOB, REN | LTB4R2 762/4885AGTR1 99/4885FTO 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.